methotrexate + methylprednisolone

Methotrexate combined with methylprednisolone is an investigational therapeutic regimen being evaluated as a first-line treatment for grade II-IV acute graft-versus-host disease (aGVHD) in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). Developed and studied primarily by researchers at Peking University People's Hospital, this combination therapy utilizes low-dose (mini-dose) methotrexate as an adjunct to standard corticosteroid therapy (methylprednisolone). Methotrexate is a small molecule antimetabolite that inhibits dihydrofolate reductase, thereby interfering with DNA synthesis and suppressing the proliferation of T-cells involved in the alloimmune response. Methylprednisolone, a synthetic glucocorticoid, provides potent anti-inflammatory and immunosuppressive effects by activating the glucocorticoid receptor. The combination is intended to enhance the efficacy of standard steroid therapy and improve complete response rates in patients with aGVHD.

Other names

mini-dose methotrexatemethotrexate and methylprednisoloneMTX + corticosteroid